newsfilter
← Latest News
ClinicalTrials.gov·

Teplizumab in Pediatric Stage 2 Type 1 Diabetes - NCT05757713

Frequency of TEAEs, AESIs, TEAEs leading to withdrawal, SAEs, Serum concentrations of teplizumab, Serum concentration of anti-teplizumab antibodies (ADA/NAb), Serum concentration of CD3 receptor occupancy on T cells